Author: NORML

Review: Thousands Of Peer-Reviewed Studies Specific To Medical Cannabis Have Been Published Over Past Decade

The total number of peer-reviewed scientific papers dedicated to cannabis, and the therapeutic use of cannabis in particular, has increased exponentially in recent years, according to data published the journal Population Health Management. Authors identified just over 29,000 cannabis-centric scientific papers published during the study period, with over 3,300 of those dedicated to the subject of medical marijuana.

Survey: Cannabis Use Becoming Common Among Older Adults

The use of cannabis is relatively common among those over the age of 65 who reside in a legal marijuana state, according to data published online in the Journal of the American Geriatrics Society. Authors concluded, “Respondents reported using recreational marijuana to target a variety of medical symptoms and conditions with few reported adverse effects.”

DEA Reclassifies Plant-Derived Marijuana Medicine To Schedule V

Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), has been reclassified today by the US Drug Enforcement Administration to Schedule V — the lowest restriction classification available under federal law. The rescheduling change is only specific to Epidiolex, and does not amend the schedule I status of either whole-plant cannabis of CBD.